CoChat

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Open access
Dawed, Adem Y, Mari, Andrea, Brown, Andrew, McDonald, Timothy J, Li, Lin, Wang, Shuaicheng, Hong, Mun-Gwan, Sharma, Sapna, Robertson, Neil R, Mahajan, Anubha, Wang, Xuan, Walker, Mark, Gough, Stephen, Hart, Leen M ‘t, Zhou, Kaixin, Forgie, Ian, Ruetten, Hartmut, Pavo, Imre, Bhatnagar, Pallav, Jones, Angus G, Pearson, Ewan R, 't Hart, L.M., Abdalla, M., Adam, J., Adamski, J., Adragni, K., Allin, K.H., Arumugam, M., Atabaki Pasdar, N., Baltauss, T., Banasik, K.B., Baum, P., Bell, J.D., Bergstrom, M., Beulens, J.W., Bianzano, S., Bizzotto, R., Bonneford, A., Brorsson, C.A.B., Brown, A.A., Brunak, S.B., Cabrelli, L., Caiazzo, R., Canouil, M., Dale, M., Davtian, D., Dawed, A.Y., De Masi, F.M., de Preville, N., Dekkers, K.F., Dermitzakis, E.T., Deshmukh, H.A., Dings, C., Donnelly, L., Dutta, A., Ehrhardt, B., Elders, P.J.M., Engel Thomas, C.E.T., Engelbrechtsen, L., Eriksen, R.G., Eriksen, R.E., Fan, Y., Fernandez, J., Ferrer, J., Fitipaldi, H., Forgie, I.M., Forman, A., Franks, P.W., Frau, F., Fritsche, A., Froguel, P., Frost, G., Gassenhuber, J., Giordano, G.N., Giorgino, T., Gough, S., Graefe-Mody, U., Grallert, H., Grempler, R., Groeneveld, L., Groop, L., Gudmundsdóttir, V.G., Gupta, R.G., Haid, M., Hansen, T., Hansen, T.H., Hattersley, A.T., Haussler, R.S., Heggie, A.J., Hennige, A.M., Hill, A.V., Holl, R.W., Hong, M.-G., Hudson, M., Jablonka, B., Jennison, C., Jiao, J., Johansen, J.J., Jones, A.G., Jonsson, A., Karaderi, T.K., Kaye, J., Klintenberg, M., Koivula, R.W., Kokkola, T., Koopman, A.D.M., Kurbasic, A, Kuulasmaa, T., Laakso, M., Lehr, T., Loftus, H., Lundbye Allesøe, R.L.A, Mahajan, A., Mari, A., Mazzoni, G.M., McCarthy, M.I., McDonald, T.J., McEvoy, D., McRobert, N., McVittie, I., Mourby, M., Musholt, P., Mutie, P, Nice, R., Nicolay, C., Nielsen, A.M.N., Nilsson, B.N., Palmer, C.N., Pattou, F., Pavo, I., Pearson, E.R., Pedersen, O., Pedersen, H.K.P., Perry, M.H., Pomares-Millan, H., Ramisch, A., Rasmussen, S.R., Raverdi, V., Ridderstrale, M., Robertson, N., Roderick, R.C., Rodriquez, M., Ruetten, H., Rutters, F., Sackett, W., Scherer, N., Schwenk, J.M., Shah, N., Sharma, S., Sihinevich, I., Sondertoft, N.B., Staerfeldt, H., Steckel-Hamann, B., Teare, H., Thomas, M.K., Thomas, E.L., Thomsen, H.S., Thorand, B., Thorne, C.E., Tillner, J., Troen Lundgaard, A.T.L., Troll, M., Tsirigos, K.D.T., Tura, A., Uhlen, M., van Leeuwen, N., van Oort, S., Verkindt, H., Vestergaard, H., Viñuela, A., Vogt, J.K, Wad Sackett, P.W.S, Wake, D., Walker, M., Wesolowska-Andersen, A., Whitcher, B., White, M.W., Wu, H. · 2023 · The Lancet Diabetes & Endocrinology
Cited by 131

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background In the treatment of type 2 diabetes, GLP-1 receptor agonists lower blood glucose concentrations, body weight, and have cardiovascular benefits. The efficacy and side effects of GLP-1 receptor agonists vary between people. Human pharmacogenomic studies of this inter-individual variation can provide both biological insight into drug action and provide biomarkers to inform clinical decision making. We therefore aimed to identify genetic variants associated with glycaemic response to GLP-1 receptor agonist treatment. Methods In this genome-wide analysis we included adults (aged ≥18 years) with type 2 diabetes treated with GLP-1 receptor agonists with baseline HbA 1c of 7% or more (53 mmol/mol) from four prospective observational cohorts (DIRECT, PRIBA, PROMASTER, and GoDARTS) and two randomised clinical trials (HARMONY phase 3 and AWARD). The primary endpoint was HbA 1c reduction at 6 months after starting GLP-1 receptor agonists. We evaluated variants in GLP1R , then did a genome-wide association study and gene-based burden tests. Findings 4571 adults were included in our analysis, of these, 3339 (73%) were White European, 449 (10%) Hispanic, 312 (7%) American Indian or Alaskan Native, and 471 (10%) were other, and around 2140 (47%) of the participants were women. Variation in HbA 1c reduction with GLP-1 receptor agonists treatment was associated with rs6923761G→A (Gly168Ser) in the GLP1R (0·08% [95% CI 0·04–0·12] or 0·9 mmol/mol lower reduction in HbA 1c per serine, p=6·0 × 10 −5 ) and low frequency variants in ARRB1 (optimal sequence kernel association test p=6·7 × 10 −8 ), largely driven by rs140226575G→A (Thr370Met; 0·25% [SE 0·06] or 2·7 mmol/mol [SE 0·7] greater HbA 1c reduction per methionine, p=5·2 × 10 −6 ). A similar effect size for the ARRB1 Thr370Met was seen in Hispanic and American Indian or Alaska Native populations who have a higher frequency of this variant (6–11%) than in White European populations. Combining these two genes identified 4% of the population who had a 30% greater reduction in HbA 1c than the 9% of the population with the worse response. Interpretation This genome-wide pharmacogenomic study of GLP-1 receptor agonists provides novel biological and clinical insights. Clinically, when genotype is routinely available at the point of prescribing, individuals with ARRB1 variants might benefit from earlier initiation of GLP-1 receptor agonists. Funding Innovative Medicines Initiative and the Wellcome Trust

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00340-0

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 131

Metadata

Authors
Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., Wang, X., Walker, M., Gough, S., Hart, L. M. ‘., Zhou, K., Forgie, I., Ruetten, H., Pavo, I., Bhatnagar, P., Jones, A. G., Pearson, E. R., 't Hart, L. M., Abdalla, M., Adam, J., Adamski, J., Adragni, K., Allin, K. H., Arumugam, M., Atabaki Pasdar, N., Baltauss, T., Banasik, K. B., Baum, P., Bell, J. D., Bergstrom, M., Beulens, J. W., Bianzano, S., Bizzotto, R., Bonneford, A., Brorsson, C. A. B., Brown, A. A., Brunak, S. B., Cabrelli, L., Caiazzo, R., Canouil, M., Dale, M., Davtian, D., Dawed, A. Y., De Masi, F. M., de Preville, N., Dekkers, K. F., Dermitzakis, E. T., Deshmukh, H. A., Dings, C., Donnelly, L., Dutta, A., Ehrhardt, B., Elders, P. J. M., Engel Thomas, C. E. T., Engelbrechtsen, L., Eriksen, R. G., Eriksen, R. E., Fan, Y., Fernandez, J., Ferrer, J., Fitipaldi, H., Forgie, I. M., Forman, A., Franks, P. W., Frau, F., Fritsche, A., Froguel, P., Frost, G., Gassenhuber, J., Giordano, G. N., Giorgino, T., Gough, S., Graefe-Mody, U., Grallert, H., Grempler, R., Groeneveld, L., Groop, L., Gudmundsdóttir, V. G., Gupta, R. G., Haid, M., Hansen, T., Hansen, T. H., Hattersley, A. T., Haussler, R. S., Heggie, A. J., Hennige, A. M., Hill, A. V., Holl, R. W., Hong, M.-G., Hudson, M., Jablonka, B., Jennison, C., Jiao, J., Johansen, J. J., Jones, A. G., Jonsson, A., Karaderi, T. K., Kaye, J., Klintenberg, M., Koivula, R. W., Kokkola, T., Koopman, A. D. M., Kurbasic, A., Kuulasmaa, T., Laakso, M., Lehr, T., Loftus, H., Lundbye Allesøe, R. L. A., Mahajan, A., Mari, A., Mazzoni, G. M., McCarthy, M. I., McDonald, T. J., McEvoy, D., McRobert, N., McVittie, I., Mourby, M., Musholt, P., Mutie, P., Nice, R., Nicolay, C., Nielsen, A. M. N., Nilsson, B. N., Palmer, C. N., Pattou, F., Pavo, I., Pearson, E. R., Pedersen, O., Pedersen, H. K. P., Perry, M. H., Pomares-Millan, H., Ramisch, A., Rasmussen, S. R., Raverdi, V., Ridderstrale, M., Robertson, N., Roderick, R. C., Rodriquez, M., Ruetten, H., Rutters, F., Sackett, W., Scherer, N., Schwenk, J. M., Shah, N., Sharma, S., Sihinevich, I., Sondertoft, N. B., Staerfeldt, H., Steckel-Hamann, B., Teare, H., Thomas, M. K., Thomas, E. L., Thomsen, H. S., Thorand, B., Thorne, C. E., Tillner, J., Troen Lundgaard, A. T. L., Troll, M., Tsirigos, K. D. T., Tura, A., Uhlen, M., van Leeuwen, N., van Oort, S., Verkindt, H., Vestergaard, H., Viñuela, A., Vogt, J. K., Wad Sackett, P. W. S., Wake, D., Walker, M., Wesolowska-Andersen, A., Whitcher, B., White, M. W., & Wu, H.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2023-01
Volume
11
Issue
1
Pages
33-41
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4312019552
Cited by
131
References
14
FWCI
11.71
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00340-0
The paper
Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., Wang, X., Walker, M., Gough, S., Hart, L. M. ‘., Zhou, K., Forgie, I., Ruetten, H., Pavo, I., Bhatnagar, P., . . . Wu, H. (2023). Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00340-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.